Tsimberidou, Apostolia Maria http://orcid.org/0000-0003-2713-233X
Hong, David S.
Fu, Siqing
Karp, Daniel D.
Piha-Paul, Sarina
Kies, Merrill S.
Ravi, Vinod
Subbiah, Vivek
Patel, Sunil M.
Tu, Shi-Ming
Janku, Filip
Heymach, John http://orcid.org/0000-0001-9068-8942
Johnson, Amber http://orcid.org/0000-0002-6202-6113
Cartwright, Carrie
Zhao, Li
Zhang, Jianhua
Berry, Donald A.
Vining, David J.
Futreal, Andrew
Miller, Vincent A.
Meric-Bernstam, Funda
Article History
Received: 27 August 2020
Accepted: 8 February 2021
First Online: 19 March 2021
Competing interests
: <b>Apostolia M. Tsimberidou: Clinical Trial Research Funding</b><b><i>(received through the institution)</i></b> IMMATICS, Parker Institute for Cancer Immunotherapy, Tempus, OBI Pharma, EMD Serono, Baxalta, ONYX, Bayer, Boston Biomedical, Placon Therapeutics, Karus Therapeutics, Tvardi, CPRIT; <b><i>Travel, Accommodations, Expenses</i></b>: ASCO, Genentech, Covance, Tempus; <b><i>Consulting or Advisory Role</i></b>: Covance, Genentech, Tempus <b>David S Hong Disclosures:</b> (last 36 months) <b><i>Research/Grant Funding (received through the institution):</i></b> AbbVie, Adaptimmune, Aldi-Norte, Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, GlaxoSmithKline, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, miRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, Takeda, Turning Point Therapeutics; <b><i>Travel, Accommodations, Expenses:</i></b> Bayer, Genmab, AACR, ASCO, P.O.E.T, CCLO, SITC; <b><i>Consulting or Advisory Role:</i></b> Alpha Insights, Amgen, Axiom, Adaptimmune, Baxter, Bayer, eCancer, Genentech, GLG, Group H, Guidepoint, Infinity,Liberium, Medscape, Numab, Oncology Education Project Association, Pfizer, Prime Oncology, Takeda, Trieza Therapeutics, WebMD. <b><i>Other ownership interests:</i></b> Molecular Match (Advisor), OncoResponse (Founder), Presagia Inc (Advisor) <b>Siqing Fu: Clinical Trial Research/Grant Funding (Received through the Institution):</b> AstraZeneca; Abbisko, Anaeropharma Science; Arrien Pharmaceuticals; BeiGene; BioAtla, LLC; Boehringer Ingelheim; Eli Lilly & Co.; Hookipa Biotech; Huya Bioscience International; IMV, Inc.; Innovent Biologics, Co., Ltd.; MacroGenics; Medivir AB; Millennium Pharmaceuticals, Inc.; Nerviano Medical Sciences; NeuPharma, Inc.; Novartis; OncoMed Pharmaceuticals; Parexel International, LLC; Sellas Life Sciences Group; Sorcimed Biopharma, Inc.; Tolero Pharmaceuticals; National Institutes of Health/National Cancer Institute; National Cancer Institute/National Institutes of Health P30CA016672 – Core Grant (CCSG Shared Resources) <b>Daniel Dr. Karp: Research/Grant Funding (received through the institution):</b> National Institutes of Health/National Cancer Institute; Myriad Drug Companies. <b>Consulting or Advisory Role:</b> BBLS; Affigen Advisory Board; Black Beret Life Scientist; Phosplatin Therapeutics Advisory Board <b>Sarina A. Piha-Paul: Research/Grant Funding (Received through the Institution):</b> AbbVie, Inc.; ABM therapeutics, Inc; Acepodia, Inc; Alkermes, Inc.; Aminex Therapeutics; Amphivena Therapeutics, Inc.; BioMarin Pharmaceutical, Inc; Boehringer Ingelheim; Bristol Myers Squib; Chugai Pharmaceutical Co., Ltd; Daichi Sankyo, Inc.; Eli Lilly; Five Prime Therapeutics; Genmab A/S; GlaxoSmithKline; Helix BioPharma Corp.; Incyte Corp.; Jacobio Pharmaceuticals Co., Ltd.; Medimmune, LLC.; Medivation, Inc.; Merck Sharp and Dohme Corp.; Novartis Pharmaceuticals; Pieris Pharmaceuticals, Inc.; Pfizer; Principia Biopharma, Inc.; Puma Biotechnology, Inc.; Rapt Therapeutics, Inc.; Seattle Genetics; Taiho Oncology; Tesaro, Inc.; TransThera Bio; National Cancer Institute/National Institutes of Health P30CA016672 – Core Grant (CCSG Shared Resources) <b>Vinod Ravi: Consulting or Advisory Role:</b> Daiichi Sankyo, Inc.; Marvin Health, Inc. <b>Other Ownership Interests:</b> UpToDate <b>Vivek Subbiah</b>: <b>Research funding/Grant support for clinical trials (received through the institution):</b> Roche/ Genentech, Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines, Loxo oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda and, National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, Turning point therapeutics, Boston Pharmaceuticals; Travel: Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte; Consultancy/ Advisory board: Helsinn, LOXO Oncology/Eli Lilly, R-Pharma US, INCYTE, QED pharma, Medimmune, Novartis. <b>Other:</b> Medscape<b>Shi-Ming Tu: Consulting or Advisory Role</b>: Janssen Biotech (Advisor) <b>Filip Janku: Research/Grant Funding (received through the institution):</b> support from Novartis, Genentech, BioMed Valley Discoveries, Astellas, Astex, Agios, Bicara, Bioxcel Therapeutics, Plexxikon, Deciphera, Piqur, Symphogen, Bristol-Myers Squibb, Asana, Merck, Ideaya Biosciences, JS Innophram, Synthorx, Sanofi, SpringBank Pharmaceuticals, SQZ Biotechnologies, Synlogic, FujiFilm Pharmaceuticals, Sotio, Novellus and Proximagen; is or has been on the Scientific Advisory Boards for Bicara, Guardant Health, Illumina, Ideaya Biosciences, IFM Therapeutics, Synlogic, Sotio, Puretech Health, Petra Pharma, Novellus and Deciphera; is a paid consultant for Cardiff Oncology and Immunomet; and has ownership interests in Cardiff Oncology. <b>John Heymach: Advisory Committee Participation:</b> ARIAD, AstraZeneca, Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, Catalyst, EMD Serono, Foundation Medicine, Hengrui Therapeutics, Genentech, Gritstone, GSK, Guardant Health, Eli Lilly, Medivation, Merck, Novartis, Oncomed, Pfizer, Roche, Sanofi, Seattle Genetics, Spectrum, Synta, Takeda. <b>Clinical Research/Grant Funding:</b> AstraZeneca, GlaxoSmithKline, Spectrum. <b>Royalties and Licensing fees:</b> Spectrum. <b>Donald Berry: Other ownership interests:</b> co-owner of Berry Consultants, LLC, a company that designs adaptive Bayesian clinical trials for pharmaceutical and medical device companies, National Institutes of Health cooperative groups, international consortia, and patient advocacy groups. <b>David J. Vining: Other ownership interests:</b> VisionSR, Majority owner and CEO, multimedia structured reporting for use in advancing medical research; Bracco Diagnostics, Inventor, virtual colonoscopy-related products for colorectal cancer imaging <b>Vincent A. Miller: Patent Royalties:</b> Memorial Sloan Kettering Cancer Center, USPO 850141. <b>Stock Holder:</b> Foundation Medicine/ROCHE; EQRX; Mirati Therapeutics. <b>Other Compensation:</b> Board of Directors, Revolution Medicines; EQRX Employee <b>Funda Meric-Bernstam: Consulting:</b> Aduro BioTech Inc., Alkermes, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., Genentech Inc., IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tyra Biosciences, Xencor, Zymeworks; <b>Advisory Committee:</b> Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, Zentalis; <b>Sponsored Research (received through the institution):</b> Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Millennium Pharmaceuticals Inc., Novartis, Puma Biotechnology Inc., Taiho Pharmaceutical Co; <b>Honoraria:</b> Chugai Biopharmaceuticals, Mayo Clinic, Rutgers Cancer Institute of New Jersey; <b>Other (Travel Related):</b> Beth Israel Deaconess Medical Center. All remaining authors have declared no conflicts of interest.